Dr. Jürg Zimmermann CML Chronic Myeloid Leukemia
"Dr. Jürg Zimmermann, a medicinal chemist, is the chemical inventor of the compound STI571 also called Gleevec''
Extract of Novartis
VIDEOS
Jürg Zimmermann & team - new treatment for Chronic Myelogenous Leukaemia
May 5, 2009, European Patent Office
Jürg Zimmermann - Drug against chronic myelogenous leukaemia - Interview
May 5, 2009, European Patent Office
Jürg Zimmermann - Drug against chronic myelogenous leukaemia - European Inventor Award
April 29, 2009, European Patent Office
Jürg Zimmermann & team - new treatment for Chronic Myelogenous Leukaemia
May 5, 2009, European Patent Office
Jürg Zimmermann - Drug against chronic myelogenous leukaemia - Interview
May 5, 2009, European Patent Office
Jürg Zimmermann - Drug against chronic myelogenous leukaemia - European Inventor Award
April 29, 2009, European Patent Office
See also History of CML
Modes of access to the website
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website.
(No registration required - Anonymous access)
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website.
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
